Investing
Proceeds from Sale of Seagen Inc. Common Stock
Bristol-Myers Squibb Proceeds from Sale of Seagen Inc. Common Stock increased by 2343.8% to $391.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3158.3%, from $12.00M to $391.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from Sale of Seagen Inc. Common Stock shows a downward trend with a -58.4% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
First reportedQ1 2021
Last reportedQ1 2026Apr 30, 2026
Metric ID:
mrk_proceeds_from_sale_of_seagen_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $409.00M | $244.00M | $1.52B | $2.00M | $148.00M | $63.00M | $5.00M | $62.00M | $5.00M | $148.00M | $0.00 | $5.00M | $55.00M | $0.00 | $205.00M | $12.00M | $0.00 | $49.00M | $16.00M | $391.00M |
| QoQ Change | — | -40.3% | +523.4% | -99.9% | >999% | -57.4% | -92.1% | >999% | -91.9% | >999% | -100.0% | — | >999% | -100.0% | — | -94.1% | -100.0% | — | -67.3% | >999% |
| YoY Change | — | — | — | — | -63.8% | -74.2% | -99.7% | >999% | -96.6% | +134.9% | -100.0% | -91.9% | >999% | -100.0% | — | +140.0% | -100.0% | — | -92.2% | >999% |
Range$0.00 – $1.52B
CAGR-0.9%
Avg YoY Growth+472.5%
Median YoY Growth-83.1%
Proceeds from Sale of Seagen Inc. Common Stock at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's proceeds from sale of seagen inc. common stock?
- Bristol-Myers Squibb (BMY) reported proceeds from sale of seagen inc. common stock of $391.00M in Q1 2026.
- How has Bristol-Myers Squibb's proceeds from sale of seagen inc. common stock changed year-over-year?
- Bristol-Myers Squibb's proceeds from sale of seagen inc. common stock increased by 3158.3% year-over-year, from $12.00M to $391.00M.
- What is the long-term trend for Bristol-Myers Squibb's proceeds from sale of seagen inc. common stock?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's proceeds from sale of seagen inc. common stock has grown at a -58.4% compound annual growth rate (CAGR), from $2.58B to $77.00M.